Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer

F Pietrantonio, R Miceli, Lorenza Rimassa, S Lonardi, G. Aprile, Alessia Mennitto, Federica Marmorino, Silvia Bozzarelli, L. Antonuzzo, Emiliano Tamburini, F Morano, D. Rossini, F Battaglin, Marina Baretti, R Berenato, Vittoria Formica, S. Mosconi, F. Petrelli, M. Ghidini, F LoupakisD Spada, S. Cinieri, G Beretta, A Falcone, F de Braud, C. Cremolini

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC.PATIENTS AND METHODS: Four hundred-eleven refractory mCRC patients with ECOG performance status (PS) ≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets.RESULTS: Four variables were selected and included in the nomogram: PS (p
Original languageEnglish
Pages (from-to)555-561
Number of pages7
JournalAnnals of Oncology
Volume28
Issue number3
DOIs
Publication statusPublished - Nov 17 2016

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., ... Cremolini, C. (2016). Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer. Annals of Oncology, 28(3), 555-561. https://doi.org/10.1093/annonc/mdw627